linjc16/ctgov huggingface dataset:
Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the toxicities of the COPPEBVCAD vs BEACOPP vs ABVD regimens.

Official Title
-----------------
Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)

Conditions
-----------------
Advanced Hodgkin Disease

Intervention / Treatment
-----------------
* Drug: COPPEBVCAD vs BEACOPP vs ABVD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed diagnosis of Hodgkin disease Clinical stage IIB, III, IV No prior treatment for Hodgkin disease or other malignancy Age 18-65 year Good cardiac, pulmunar, renal and hepatic function Performance status 0-3 (Karnofsky 100- 40) Written Informed Consent Exclusion Criteria: HIV positivity Large cell, anaplastic, CD30+ lymphoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: abvd<br> | Drug: COPPEBVCAD vs BEACOPP vs ABVD<br> <br> |
| Experimental: beacopp<br> | Drug: COPPEBVCAD vs BEACOPP vs ABVD<br> <br> |
| Experimental: coppebvcad<br> | Drug: COPPEBVCAD vs BEACOPP vs ABVD<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the toxicity of the COPPEBVCAD vs BEACOPP vs ABVD regimens |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the results in terms of response, failure free survival and relapse free survival of the three regimens |  |  |
Neuromuscular Warm-up Intervention to Improve Postural Control in Female Handball Players

Study Overview
=================
Brief Summary
-----------------
Female handball athletes are at a particular risk of sustaining lower extremity injuries. The study examines time-dependent adaptations of static and dynamic balance as potential injury risk factors to a specific warm-up program focusing on neuromuscular control.

Official Title
-----------------
Efficacy of a Specific Warm-up Program to Improve Static and Dynamic Postural Control in Adult Female Handball Players

Conditions
-----------------
Postural Balance

Intervention / Treatment
-----------------
* Behavioral: Neuromuscular warm-up
* Behavioral: Standard warm-up


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gender: Female Handball players Actively participated in competitions Uninjured at study enrollment Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neuromuscular<br>Neuromuscular warm-up | Behavioral: Neuromuscular warm-up<br>* The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.<br>|
| Active Comparator: Control<br>Standard warm-up | Behavioral: Standard warm-up<br>* Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline: Static postural control | Postural sway (center of pressure sway velocity) during unipedal quiet standing, eyes opened (20 seconds) | 3, 6, 9, and 11 weeks | 
| Change from Baseline: Dynamic postural control | Star Excursion Balance Test (SEBT) | 3, 6, 9, and 11 weeks |
Vertical Split Conjunctival Autograft in Double-head Pterygia

Study Overview
=================
Brief Summary
-----------------
15 eyes of 15 patients with primary double-headed pterygia that underwent vertical split conjunctival autograft pterygium surgery were retrospectively reviewed. All patients had primary double-headed pterygia. Recurrence was defined as fibrovascular proliferation over the limbus onto the cornea. Vertical split conjunctival autograft using fibrin glue is an effective technique with good cosmetic results and low to no recurrence for primary double head pterygia treatment.

Detailed Description
-----------------
The pterygium body was dissected from the sclera. Complete excision of the pterygium, subconjunctival Tenon's tissue and surrounding fibrovascular tissues followed.The conjunctival edge was trimmed. The corneal surface was gently scraped with a scalpel. The Same procedure was done on temporal pterygia. A free conjunctival autograft was obtained. The graft was divided vertically into two parts. The nasal part of the graft was cut from limbal attachment including limbal tissue; temporal part was left attached. The nasal part of the graft was moved to the nasal conjunctival defect and attached to the sclera with fibrin sealant (Tisseel; Baxter, Vienna, Austria). The Same procedure was done with the temporal part of the graft. The orientation of graft was ensured before securing it.

Official Title
-----------------
Outcomes of Vertical Split Conjunctival Autograft Using Fibrin Glue in Treatment of Primary Double-head Pterygia

Conditions
-----------------
Pterygium of Conjunctiva and Cornea

Intervention / Treatment
-----------------
* Procedure: Double head pterygia excision and repair


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary double-headed pterygia Exclusion Criteria: NONE

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Double head pterygia excision and repair|Complete excision of the pterygia was done. A free conjunctival autograft was obtained. The graft was divided vertically into two parts then secured into conjunctival defects.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The recurrence rate | ﬁbrovascular tissue invading the cornea and expressed as a percentage | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pterygium, double-headed, vertical
Effect of Aerobic Exercise Training in Obese Adults

Study Overview
=================
Brief Summary
-----------------
To determine the effect of aerobic exercise training on arterial stiffness and hemodynamics in obese adults. Proper evidence on the effect of aerobic exercise training on both arterial stiffness and hemodynamics are sparsely present in obese adults whereas separate studies were done in mainly hypertensive and cardiovascular disease populations.

Detailed Description
-----------------
Obese adults always have been trying to improve their quality of life by managing the complications associated with obesity like arterial stiffness and disturbed hemodynamics.

Official Title
-----------------
Effect of Aerobic Exercise Training on Arterial Stiffness and Hemodynamics in Obese Adults.

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: Aerobic exercise training
* Other: Conventional therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body mass index ≥28 kg/m² Able to do exercise Exclusion Criteria: Involved in structured physical activity in last 6 months History of chronic systemic disease (cardiovascular, pulmonary, and metabolic disease) Continuous medication use. MSK or Neurological problems Pregnant females

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Aerobic exercise training<br>hospital-based aerobic exercise training on treadmill/cycle ergometer with the intensity of 40-70% of HR max, for 15-30 mints for 8 weeks | Other: Aerobic exercise training<br>* Hospital-based aerobic exercise training for 15-30 minutes including pre and post-vitals assessment. 3x/week on alternate days for 8 weeks at 40-70% of HR Max<br>|
| Active Comparator: Conventional therapy<br>Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks | Other: Conventional therapy<br>* Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial Stiffness | Gradual fragmentation and loss of elastin fibers and accumulation of stiffer collagen fibers in the arterial wall. Calculated through Arterial stiffness index. | 6 weeks | 
| Hemodynamics | Factors that govern blood flow calculated through Rate Pressure Product. | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aerobic exercise, arterial stiffness, hemodynamics, obesity
Neuromodulation Parameter Efficacy

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine the efficacy of neuromodulation using various stimulation paradigms in the treatment of several disorders including chronic pain.

Detailed Description
-----------------
Different stimulation parameters will be tried in a blinded fashion to compare efficacy.

Official Title
-----------------
Evaluating the Efficacy of Different Stimulation Paradigms in Neuromodulation

Conditions
-----------------
Chronic Pain

Intervention / Treatment
-----------------
* Other: Stimulation parameters


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are candidates for, and have been consented for, implantation of a neuromodulation device. Exclusion Criteria: Non-English speaking

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Industry standard stimulation<br>Industry standard stimulation settings | Other: Stimulation parameters<br>* Different device stimulation parameters<br>|
| Sham Comparator: Experimental stimulation<br>Experimental stimulation settings | Other: Stimulation parameters<br>* Different device stimulation parameters<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in baseline pain measures | Pain outcomes measured using visual analogue scale | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of stimulation on quality of life | As measured using EQ-5D-3L | 6 months |
Cardiac Biomarker in Pediatric Heart Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate cardiac biomarker during perioperative management in pediatric cardiac surgery.

Official Title
-----------------
Observational Study of Cardiac Biomarker During Perioperative Management in Pediatric Heart Disease

Conditions
-----------------
Congenital Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children who receive surgery for congenital heart disease require cardiopulmonary bypass for surgery under 18 years old Exclusion Criteria: simple congenital heart disease (atrial septal defect, ventricle septal defect, patent ductus arteriosus)

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serious adverse events |  | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac biomarker, congenital heart disease, surgery
Middle Ear Pressure Disregulation After Tympanostomy Tube Insertion

Study Overview
=================
Brief Summary
-----------------
This study will determine if the investigators can use certain tests (eustachian tube function tests and gas exchange tests) to predict whether or not a child who had tubes surgically placed in their eardrum because of middle-ear disease will redevelop the disease again after the tubes quit working.

Detailed Description
-----------------
This study will enroll children 3-6 years of age with tympanostomy tubes inserted for otitis media with effusion (OME)and measure middle ear gas demand, middle ear volume and eustachian tube function longitudinally between the time of tube insertion and extrusion/nonfunctioning. The data will be used to test the hypotheses that: gas transfer across the middle ear mucosa decreases in phase with resolution of middle ear inflammation and effusion; gas transfer across the middle ear mucosa is increased by an episode of otorrhea; eustachian tube function is unaffected by tympanostomy tube insertion, and measurement of eustachian tube function and trans-middle ear mucosa gas transfer predicts disease recurrence and presentation after tube extrusion/nonfunctioning. The results of these studies will be used to support or refute tested components of existing models of middle ear pressure-regulation and to develop test protocols for risk assignments with respect to disease recurrence in individual ears after tympanostomy tube extrusion/nonfunctioning.

Official Title
-----------------
Middle Ear Pressure Disregulation After Tympanostomy Tube Insertion

Conditions
-----------------
Otitis Media With Effusion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 3-6 years old History of chronic otitis media with effusion(OME) Scheduled or within 6 weeks of tube insertion OME at entry or surgery Generally good health Exclusion Criteria: Cleft palate or other syndromes predisposing to OM History of recurrent acute otitis media only History of complications of OM or its treatment Unable to cooperate for testing

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Children with tympanostomy tubes for chronic OME | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| middle ear status | middle-ear status at 12 months after tympanostomy tube became non-functional | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
otitis media, tympanostomy tube, eustachian tube function, gas exchange, tympanostomy tubes
Neonatal Erythropoietin in Asphyxiated Term Newborns

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and pharmacokinetics of moderate to high doses of erythropoietin in newborn infants with birth asphyxia.

Detailed Description
-----------------
Newborn infants with birth asphyxia are at high risk of death or long-term neurologic disability; yet therapies for birth asphyxia are currently limited. Erythropoietin (Epo) is a FDA-approved drug that is an effective neuroprotective agent in animal models of birth asphyxia. This is a phase I dose finding multi-center trial that will test the safety and pharmacokinetics of Epo in human infants with birth asphyxia. The long-term objectives of the proposed research are to reduce mortality and to decrease the risk of long-term disabilities in infants who survive beyond the newborn period.

Official Title
-----------------
Neonatal Erythropoietin in Asphyxiated Term Newborns: a Phase I Trial

Conditions
-----------------
Hypoxic-ischemic Encephalopathy

Intervention / Treatment
-----------------
* Drug: erythropoietin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 36 weeks gestational age Perinatal depression (low Apgar score, need for resuscitation) Moderate to severe encephalopathy Exclusion Criteria: Specific aEEG findings Intrauterine growth restriction Severe congenital anomaly, genetic syndrome, metabolic disorder, arthrogryposis, TORCH infection Microcephaly Infant older than 23.5 hours of age at the time of consent Infant judged by an attending physician to be likely to die due to the severity of illness Polycythemia Hypertension No in-dwelling line

Ages Eligible for Study
-----------------
Maximum Age: 24 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>All enrolled patients will be in this single arm, who will receive experimental drug treatment. | Drug: erythropoietin<br>* 250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)<br>* Other names: Procrit;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serious adverse event |  | 14 days of life | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetic parameters |  | 1 to 11 days of life | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
birth asphyxia, neonatal encephalopathy, hypoxic-ischemic encephalopathy, neuroprotection, neonate
Constitution of a Cohort for Monitoring Patients Candidating for Ovarian Tissue Autograft

Study Overview
=================
Brief Summary
-----------------
Ovarian cryopreservation is one of the available option for preserving fertility prior to potentially sterilizing treatments. In the absence of other techniques such as in vitro folliculogenesis or injection of isolated ovarian follicles, this tissue can only be re-used by autograft. In France, the first live birth after orthotopic ovarian transplantation, was obtained by Roux et al. in 2009. This clinical trial aims to build a cohort of patients likely to use their ovarian tissue cryopreserved by autograft.

Detailed Description
-----------------
Ovarian cryopreservation is one of the available option for preserving fertility prior to potentially sterilizing treatments. In the absence of other techniques such as in vitro folliculogenesis or injection of isolated ovarian follicles, this tissue can only be re-used by autograft. In France, the first live birth after orthotopic ovarian transplantation, was obtained by Roux et al. in 2009. This clinical trial aims to build a cohort of patients likely to use their ovarian tissue cryopreserved by autograft. This cohort will be used to: Follow up of patients with their cryopreserved ovarian tissue; Evaluate requests for ovarian tissue grafting ; Propose a search of residual disease in case of neoplastic disease risk (if possible); Allowing patients to benefit from an ovarian tissue autograft; Assess the effectiveness of autograft technique after the restoration of ovarian function.

Official Title
-----------------
Constitution of a Cohort for Monitoring Patients Candidating for Ovarian Tissue Autograft

Conditions
-----------------
Ovarian Function Insufficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have cryopreserved their ovarian tissue; Patients with premature ovarian insufficiency; Patients older than 11 years (bone age) for induction of puberty; Patients aged from 18 to 43 years for the restoration of ovarian function; No objection from the patient Patients who have already received ovarian tissue autograft. Exclusion Criteria: Patients aged under 11 years (bone age); Patients older than 43 years; Patients refusing to be included; Patients (adults) under guardianship, curators and safeguard justice

Ages Eligible for Study
-----------------
Minimum Age: 11 Years
Maximum Age: 43 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patient who are candidate to ovarian tissue autograft |  | 5 years |